Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs W W Grainger Inc (GWW) Price & Performance

Amgen, Inc.Trade
W W Grainger IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs W W Grainger Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while W W Grainger Inc trades at $1,305.49 (market cap $61.32B). The key difference: Amgen, Inc. is far larger — about 3.7× W W Grainger Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.

AMGNGWW
Market Cap
$224.14B$61.32B
Sector
HealthTechnology
52-Week High
$417.20$1.40K
52-Week Low
$271.18$918.18
Enterprise Value
$267.45B$63.53B
Dividend Yield
2.43%0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.

Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.

W W Grainger Inc

W.W. Grainger (GWW) trades at $1,308.06, up 0.82% on the day, with strong recent earnings beats in Q1 and Q2 2026. The stock shows a bearish technical signal despite robust fundamentals, including a 47.92% ROE and rising revenue. Analysts maintain a cautious stance with a consensus price target of $1,320, while recent news highlights operational strength and market share gains.

Outlook remains mixed; solid earnings growth and margin expansion support upside, but high valuation multiples and bearish technicals pose near-term risks. Investors should weigh strong cash flow and dividend stability against potential volatility from macroeconomic pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW